About Innova Vascular
Leadership
Dr. Sanjay Shrivastava is the founder and CEO of Innova Vascular. Sanjay has been involved in developing, commercializing, evaluating, and acquiring medical devices for over 20 years. During his career, Sanjay has held leadership positions at leading medical device companies including senior director, business development at Johnson & Johnson, vice president, upstream marketing and strategy at BTG, plc. (acquired by Boston Scientific Corporation), director global marketing at Medtronic, and director, research & development at Covidien/ev3 (merged with Medtronic). Sanjay cofounded BlackSwan Vascular, a medical device startup company, which received FDA approval for its Lava liquid embolic agent for peripheral vascular use. BlackSwan was acquired by Boston based Sirtex Medical and its parent company in April 2023. Additionally, Sanjay serves as a member of the board of directors at enVVeno Medical Corporation (Nasdaq: NVNO).
Dr. Owen O’Niell
Orthopedic Surgeon & President
Twin Cities Orthopedics
Dr. Sanjay Shrivastava
Chief Executive Officer
Innova Vascular, Inc.
Michael J. Hennessy, Jr.
Chief Executive Officer and
President for MJH Life Sciences™
Ana Quintana
Managing Partner
Black Diamond Ventures
Board Observer
Federico Aloisi
Investment Director
Geo Medtech Ventures
Board Observer
John Zehren
Commercial Advisor
Innova Vascular’s Laguna® Thrombectomy System Surpasses Primary Endpoints in Pivotal TRUST Study for Pulmonary Embolism
IRVINE, CA, UNITED STATES, October 5, 2026 /EINPresswire.com/ — Innova Vascular, Inc., a medical technology company developing minimally invasive treatments for blood clots in the vascular system, today announced positive results from its pivotal TRUST (Treating Pulmonary Embolism with Laguna Thrombectomy System) study evaluating the Laguna® Thrombectomy System for the treatment of pulmonary embolism (PE).
Innova Vascular Completes Enrollment in Trust IDE Study Evaluating the Laguna Thrombectomy System™ for Pulmonary Embolism
IRVINE, CA, UNITED STATES, August 31, 2026 /EINPresswire.com/ — Innova Vascular, Inc., a medical technology company developing innovative endovascular solutions for the treatment of vascular thromboembolism, today announced the completion of patient enrollment in the TRUST pivotal Investigational Device Exemption (IDE) clinical study evaluating the safety and effectiveness of the Laguna® Thrombectomy System for the treatment of pulmonary embolism (PE).
Innova Vascular Announces Successful Early Commercial Use of Laguna Thrombectomy System™ in Patients
IRVINE, Calif., Feb. 7, 2024 /PRNewswire/ — Innova Vascular, Inc. today announced successful early commercial use of the company’s Laguna Thrombectomy System™. Physicians at UCLA Medical Center in Los Angeles, California, and Providence St. Joseph in Orange, California, who were the first to use this system in patients, have reported positively on their experience.
Innova Vascular Earns FDA Clearance for Two New Thrombectomy Devices: Laguna Clot Retriever™ System and Malibu Aspiration Catheter™ System
IRVINE, Calif, June 7, 2023 /PRNewswire/ — Innova Vascular, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Laguna Clot Retriever™ System and its Malibu Aspiration Catheter™ System for use in the peripheral vasculature. The two new devices are collectively known as the Laguna Thrombectomy System.
Contact us
If you have an interest in being part of our journey as employees, suppliers, consultants or in any other capacity, please email us.
Innova Vascular, Inc. 15375
Barranca Parkway, B-101
Irvine, CA 92618
Innova Vascular, Inc. 15375
Barranca Parkway, B-101
Irvine, CA 92618